Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lakshminarayan

Showing results (581-590 of 585) with videos related to

Pageof 59
Sort By:
You have reached the last page of results.This site can display upto 585 results.
Annals of the Rheumatic Diseases|December 6, 2014
Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatmentLakshminarayan R Ranganath, Anna M Milan, Andrew T Hughes, et al.
Annals of the Rheumatic Diseases|December 20, 2023
Randomised trial of genetic testing and targeted intervention to prevent the development and progression of Paget's disease of boneJonathan Phillips, Deepak Subedi, Steff C Lewis, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 17, 2020
Characteristics of Early Paget's Disease in SQSTM1 Mutation Carriers: Baseline Analysis of the ZiPP Study CohortOwen Cronin, Deepak Subedi, Laura Forsyth, et al.
BMJ Open|September 7, 2019
Zoledronate in the prevention of Paget's (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent <i>SQSTM1</i>-mediated Paget's disease of boneOwen Cronin, Laura Forsyth, Kirsteen Goodman, et al.
The Lancet. Diabetes & Endocrinology|August 22, 2020
Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trialLakshminarayan R Ranganath, Eftychia Eirini Psarelli, Jean-Baptiste Arnoux, et al.
Pageof 59

Showing results (581-590 of 585) with videos related to

Sort By:
Pageof 59
You have reached the last page of results.This site can display upto 585 results.
Annals of the Rheumatic Diseases|December 6, 2014
Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatmentLakshminarayan R Ranganath, Anna M Milan, Andrew T Hughes, et al.
Annals of the Rheumatic Diseases|December 20, 2023
Randomised trial of genetic testing and targeted intervention to prevent the development and progression of Paget's disease of boneJonathan Phillips, Deepak Subedi, Steff C Lewis, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 17, 2020
Characteristics of Early Paget's Disease in SQSTM1 Mutation Carriers: Baseline Analysis of the ZiPP Study CohortOwen Cronin, Deepak Subedi, Laura Forsyth, et al.
BMJ Open|September 7, 2019
Zoledronate in the prevention of Paget's (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent <i>SQSTM1</i>-mediated Paget's disease of boneOwen Cronin, Laura Forsyth, Kirsteen Goodman, et al.
The Lancet. Diabetes & Endocrinology|August 22, 2020
Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trialLakshminarayan R Ranganath, Eftychia Eirini Psarelli, Jean-Baptiste Arnoux, et al.
Pageof 59